Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Commentary|Videos|November 17, 2026

Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

In the second segment of an interview with BioPharm International®, Dave Maraldo, PhD, executive vice president and president of Merck Manufacturing Division, examines what biologics manufacturing can learn from small-molecule plants and how capital investment can preserve flexibility for bioconjugation. Both points centered on how platform thinking can carry across molecule types.

"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process."

Dr Maraldo says small-molecule manufacturing offers lessons in platform agility for biologics. Small-molecule facilities treat unit operations as interchangeable, such as roller compaction or wet granulation, and sequence them based on what each molecule needs. He emphasizes that biologics can head in that direction. Purifying and then conjugating a peptide or an antibody, for example, is still bioconjugation. He also asks what small molecules can teach biologics about platform agility, while noting that biologics carry many sensitivities and differences.

How can capital investment keep bioconjugation flexible?

Asked whether this investment strategy amounts to a trial-and-error approach, Dr Maraldo says that it links to core technologies, and conjugation is key know-how. Many methods exist, he emphasizes. Manufacturers can conjugate in a stainless-steel reactor or in a single-use assembly. The challenge, he notes, is to structure capital investment so the network can respond when researchers report that a molecule is sensitive to stainless steel and needs a bag.

"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process," he explains.

Some capabilities already overlap between the 2 worlds, he says. Many small-molecule programs, and the wider industry, use enzymes, and producing an enzyme involves an Escherichia coli fermentation, a form of cell culture. Dr Maraldo points out that those capabilities are quite analogous between small molecules and large molecules. Those shared capabilities show where learning can transfer, he adds.

Learn more from the first segment of Dr Maraldo’s interview. To gain more insight on Merck, watch an exclusive interview with Dr Maraldo on Pharmaceutical Executive, a sister brand under MJH Life Sciences.

About the speaker

Dave Maraldo, PhD, Executive Vice President and President, Merck Manufacturing Division

Dr Maraldo has responsibility for Merck’s worldwide human health manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines and biologics. Since joining the company as a project engineer in 1999, he progressed through a range of leadership roles across manufacturing, technical operations, commercialization and integrated development and supply. Building on that foundation, he led global biologics operations from 2022- 2025 and most recently served as senior vice president of human health manufacturing. Dr Maraldo earned his PhD and master of chemical engineering degrees from Drexel University, an MBA degree from Lehigh University and a bachelor of chemical engineering degree from Widener University.


Related to this article